VisiJet Inc. dba Advanced Refractive Technologies Receives Approval to Sell EpiLift System in Canada.

SAN CLEMENTE, Calif. -- VisiJet Inc. (OTC BB: VJET), dba Advanced Refractive Technologies (ART), a developer and marketer of innovative technologies for the ophthalmic surgical market, received licensed approval from Health Canada, the federal department responsible for helping the people of Canada maintain and improve their health, to market and sell the EpiLift System in Canada.

The EpiLift System is already being sold in over 30 countries including the United States, Japan and in most countries in Europe. The system is the cornerstone of Epi-LASIK, a new, safer method of the popular LASIK corrective vision surgery.

"Canada is a difficult market to enter due to its stringent safety requirements, which are very similar to those in the United States. Gaining this approval from Health Canada is further testimony to the efficacy and safety of the EpiLift device. It is also an extremely important market that will enable us to expand our North American reach." said Randy Bailey, CEO.

About the EpiLift System

When the EpiLift System is used, the epithelium - the top layer of the eye - is cleanly separated, at a natural division point in the eye, from the Bowman's layer membrane in an intact sheet of viable tissue. The tissue is then lifted away from the cornea so that a laser can be applied to reshape it. This entire process, Epi-LASIK, produces virtually instant visual results similar to LASIK but with the stable long-term visual outcomes of PRK.

LASIK surgery, currently a standard corrective vision surgical process, requires making a flap in the top layer of the eye before the laser is applied. This flap, once created, never fully heals, which can lead to complications and possible vision impairment in the future. Because it does not involve cutting the cornea or creating a permanent flap, the EpiLift System allows the eye to regrow the connections with the epithelium, resulting in a safer procedure with a significantly lower risk of complications.

About Advanced Refractive Technologies

Advanced Refractive Technologies (ART) formerly VisiJet Inc., is a medical device company based in Irvine, California focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in Lasik surgery called Epi-LASIK. The EpiLift system improves upon existing technologies using a unique separating method that eliminates many postoperative problems. Gebauer Medizintechnik GmbH, a German engineering firm, developed and manufactures the EpiLift System.

In addition to the EpiLift system, ART is currently developing Pulsatome(R), which utilizes the company's proprietary and patented waterjet technology. The Pulsatome(R) cataract emulsifier is a device that uses pulsed waterjet technology to remove cataracts - the most frequently performed surgical procedure in the world. Both of these products result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries.

For additional information please visit: www.visijet.com

This release contains forward-looking statements that reflect the company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other regular filings.